Hydroxychloroquine in Rheumatoid Arthritis Treatment

Role in Rheumatoid Arthritis Management

• Hydroxychloroquine is classified as a conventional synthetic disease-modifying antirheumatic drug (csDMARD) for rheumatoid arthritis (RA) treatment, and it is most commonly used as part of combination therapy, particularly in the frequently used triple therapy regimen consisting of methotrexate, sulfasalazine, and hydroxychloroquine 1, 2
• According to the 2019 EULAR recommendations, hydroxychloroquine has shown only weak clinical efficacy and no structural efficacy in RA treatment based on historic studies 1

Efficacy and Position in Treatment Algorithm

• Current guidelines position hydroxychloroquine as having a limited place in RA treatment, mainly reserved for patients with mild disease activity 1, 2
• The 2019 EULAR recommendations focus more on sulfasalazine and leflunomide as preferred csDMARDs due to their superior efficacy 1

Dosing and Administration

• The American College of Rheumatology recommends a maximum daily dose of 5 mg/kg based on actual body weight to minimize retinal toxicity risk 3

Combination Therapy

• The most frequently used combination consists of methotrexate, sulfasalazine, and hydroxychloroquine 1

Safety Considerations

• The main safety concern is retinal toxicity, which is dose and duration dependent, and monitoring recommendations include baseline ophthalmologic examination and annual screening after 5 years of therapy for low-risk patients 3

Clinical Decision Making

• When choosing between hydroxychloroquine and other DMARDs, consider disease severity, as hydroxychloroquine is more appropriate for mild disease 1, 2

Role of Hydroxychloroquine in Rheumatoid Arthritis Management

Mechanism of Action

• Hydroxychloroquine concentrates in intracellular acidic vesicles (endosomes/lysosomes), becomes protonated, raises vesicular pH, and inhibits pH‑dependent proteases that process inflammatory mediators such as tumor‑necrosis factor‑α and interleukin‑6, thereby modulating immune‑cell activity and attenuating inflammation【4】.

Clinical Efficacy Profile

• Evidence from systematic reviews indicates that hydroxychloroquine provides only weak clinical benefit and no structural protection against joint damage in rheumatoid arthritis, making it substantially less effective than methotrexate【5】 (moderate‑quality evidence).

Position in Treatment Guidelines

• The European League Against Rheumatism (EULAR) recommends that hydroxychloroquine be reserved for patients with mild disease activity or used as part of combination therapy, rather than as first‑line monotherapy for DMARD‑naïve individuals with moderate‑to‑high disease activity【5】.
• EULAR also lists sulfasalazine and leflunomide as preferred conventional synthetic DMARDs over hydroxychloroquine because of superior efficacy【5】.

Combination Therapy (Triple Therapy)

• In patients who have an inadequate response to methotrexate alone, adding sulfasalazine and hydroxychloroquine to methotrexate (triple therapy) is supported as an effective regimen【6】 (high‑quality evidence from randomized trials).
• For DMARD‑naïve patients with moderate‑to‑high disease activity, methotrexate is strongly recommended over hydroxychloroquine due to its greater disease‑modifying properties and better long‑term tolerability【6】.

Hydroxychloroquine as the Preferred csDMARD for Rheumatoid Arthritis Patients Undergoing Breast Cancer Treatment

Safety Profile Compared with Leflunomide

• Leflunomide is immunosuppressive and has a prolonged half‑life due to enterohepatic recirculation, making it difficult to manage if complications arise during concurrent cancer therapy【7】.
• The American College of Rheumatology conditionally recommends methotrexate over leflunomide for safety reasons; this same safety concern supports choosing hydroxychloroquine rather than leflunomide in high‑risk populations such as patients receiving active cancer treatment【8】.

Disease‑Activity Guidance

• The 2020 EULAR guideline recommends hydroxychloroquine for patients with mild‑to‑moderate rheumatoid arthritis or as part of combination therapy, rather than for aggressive disease【9】.
• The 2019 EULAR recommendations state that patients with low disease activity have a low propensity for joint destruction, so the limited structural efficacy of hydroxychloroquine is acceptable in appropriately selected patients【7】.

Initial Assessment and Treatment Decision

• If the patient’s rheumatoid arthritis is mild‑to‑moderate without aggressive erosive changes, hydroxychloroquine is an appropriate first‑line conventional synthetic DMARD【9】.
• In cases of severe, highly active rheumatoid arthritis with poor prognostic factors (e.g., high autoantibody levels, early joint damage), hydroxychloroquine alone may be insufficient for disease control, but it remains the safer option compared with leflunomide during active cancer treatment【7】【9】.

Monitoring and Therapy Adjustment

• RA disease activity should be reassessed every 1–3 months; if no clinical improvement is observed by 3 months or the treatment target is not achieved by 6 months, the therapeutic regimen should be modified【9】【8】.

Bridging Strategies When Hydroxychloroquine Is Insufficient

• For patients with severe active rheumatoid arthritis during cancer therapy, a short‑term bridging approach using low‑dose glucocorticoids (≤10 mg/day prednisone‑equivalent) is recommended until cancer treatment is completed, after which more aggressive DMARDs or biologics can be reconsidered【8】.